| 证券代码 | GNMX.O |
| 证券名称 | Aevi Genomic Medicine Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2016-10-21 |
| 首发价格(元) | 4.54 |
| 首发数量(股) | 2460000 |
| 首发募资额(元) | 11,168,400.00 |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Aevi Genomic Medicine, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 435 Devon Park Drive, Suite 715, Wayne, Pennsylvania, USA |
| 成立日期 | 2000-01-27 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.aevigenomics.com |
| 电话 | +1 (610) 254-4201 |
| 传真 | - |
| 公司简介 | Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). |